Cardiovascular disease in patients with renal disease: The role of statins

Current Medical Research and Opinion

Volumn 25, Issue 1, 2009, Pages 271-285

  Fellström, Bengt ^a   Holdaas, Hallvard ^b   Jardine, Alan G ^c   Svensson, Maria K ^d   Gottlow, Mattis ^d   Schmieder, Roland E ^e   Zannad, Faiez ^f  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d ASTRAZENECA R AND D   (Sweden)

^e UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^f Ctr Hospitalier Univ de Nancy   (France)

Author keywords

Cardiovascular; Chronic kidney disease; Dialysis; Dyslipidaemia; Statin

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN B; ATORVASTATIN; BILE ACID SEQUESTRANT; C REACTIVE PROTEIN; CALCIUM PHOSPHATE; CREATININE; CYTOCHROME P450 3A4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FETUIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PARATHYROID HORMONE; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DATA BASE; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFECT; DRUG TOLERABILITY; DYSLIPIDEMIA; FOLLOW UP; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HORMONE RELEASE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFORMATION RETRIEVAL; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY GRAFT; LOW DRUG DOSE; MEDLINE; MICROALBUMINURIA; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PERITONEAL DIALYSIS; PROTEINURIA; RENAL REPLACEMENT THERAPY; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SYSTEMATIC REVIEW; CHRONIC DISEASE; KIDNEY DISEASE; RISK FACTOR;

CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; RISK FACTORS;

EID: 64249092502     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802622064     Document Type: Review

References (107)

1. Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 2008;8:117 (Pubitemid 351678123)
2. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-2047 (Pubitemid 350074801)
3. Bommer J. Prevalence and socio-economic aspects of chronic kidney disease. Nephrol Dial Transplant 2002;17 (Suppl 11):8-12 (Pubitemid 35277055)
4. U.S. Renal Data System, USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2006
5. Xue JL, Ma JZ, Louis TA, et al. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001;12:2753-2758 (Pubitemid 33115423)
6. Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol 2002;13(Suppl 1):S37-40
7. Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006;17:2034-2047 (Pubitemid 44036188)
8. Briggs JD. Causes of death after renal transplantation. Nephrol Dial Transplant 2001;16:1545-1549 (Pubitemid 32750442)
9. Johnson DW, Craven AM, Isbel NM. Modification of cardiovascular risk in hemodialysis patients: an evidence-based review. Haemodial Int 2007;11:1-14 (Pubitemid 46128673)
10. Tomilina NA, Storozhakov GI, Gendlin GE, et al. Risk factors and pathogenetic mechanisms of left ventricular hypertrophy in progressive chronic kidney disease and after transplantation of the kidney. Ter Arkh 2007;79:34-40
11. Molitch ME. Management of dyslipidemias in patients with diabetes and chronic kidney disease. Clin J Am Soc Nephrol 2006; 1:1090-1099
12. Goodman WG. Calcimimetics: a remedy for all problems of excess parathyroid hormone activity in chronic kidney disease? Curr Opin Nephrol Hypertens 2005;14:355-360
13. Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-617 (Pubitemid 28158000)
14. Fabbian F, Catalano C, Orlandi V, et al. Evaluation of aortic arch calcification in hemodialysis patients. J Nephrol 2005; 18:289-293 (Pubitemid 41078948)
15. Sarnak MJ. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 2003;41(Suppl 5):S11-17 (Pubitemid 36637964)
16. Braun J, Asmus HG, Holzer Hospital, et al. Long-term comparison of a calcium-free phosphate binder and calcium carbonate- phosphorus metabolism and cardiovascular calcification. Clin Nephrol 2004;62:104-115 (Pubitemid 39162762)
17. Chertow GM, Raggi P, Chasan-Taber S, et al. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004;19:1489-1496 (Pubitemid 38786743)
18. Annuk M, Soveri I, Zilmer M, et al. Endothelial function, CRP and oxidative stress in chronic kidney disease. J Nephrol 2005;18:721-726 (Pubitemid 43085438)
19. Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007;71:438-441 (Pubitemid 46303553)
20. Attman PO, Alaupovic P, Tavella M, et al. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure. Nephrol Dial Transplant 1996;11:63-69 (Pubitemid 26038466)
21. Kasiske BL, Lakatua JD, Ma JZ, et al. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis 1998;31:954-961 (Pubitemid 28265191)
22. Deighan CJ, Caslake MJ, McConnell M, et al. Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis 2000;35:852-862 (Pubitemid 30238197)
23. Attman PO, Knight-Gibson C, Tavella M, et al. The compositional abnormalities of lipoproteins in diabetic renal failure. Nephrol Dial Transplant 1998;13:2833-2841 (Pubitemid 28479531)
24. Muntner P, Hamm LL, Kusek JW, et al. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 2004;140:9-17 (Pubitemid 38055916)
25. Kimak E, Solski J. ApoA- and apoB-containing lipoproteins and Lp(a) concentration in non-dialyzed patients with chronic renal failure. Ren Fail 2002;24:485-492 (Pubitemid 34913058)
26. Karie S, Launay-Vacher V, Deray G, et al. [Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant.] Presse Med 2006;35:219-229
27. Tonelli M. The effect of statins on preservation of kidney function in patients with coronary artery disease. Curr Opin Cardiol 2006;21:608-612 (Pubitemid 44624548)
28. Chan DT, Irish AB, Dogra GK, et al. Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials. Atherosclerosis 2008;196:823-834
29. Prichard SS. Impact of dyslipidemia in end-stage renal disease. J Am Soc Nephrol 2003;14(Suppl 4):S31-20 (Pubitemid 37052397)
30. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003;41(Suppl 3):S1-91
31. Attman PO, Samuelsson OG, Moberly J, et al. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. Kidney Int 1999;55:1536-1542 (Pubitemid 29157154)
32. Moberly JB, Attman PO, Samuelsson O, et al. Alterations in lipoprotein composition in peritoneal dialysis patients. Perit Dial Int 2002;22:220-228 (Pubitemid 34546334)
33. Llopart R, Doñate T, Oliva JA, et al. Triglyceride-rich lipoprotein abnormalities in CAPD-treated patients. Nephrol Dial Transplant 1995;10:537-540
34. Kronenberg F, König P, Neyer U, et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1995;6:110-120
35. Iseki K, Yamazato M, Tozawa M, et al. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 2002;61:1887-1893 (Pubitemid 34437945)
36. Kasiske B, Cosio FG, Beto J, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 2004;4(Suppl 7):13-53 (Pubitemid 38436863)
37. Shoji T, Nishizawa Y, Kawagishi T, et al. Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol 1998;9:1277-1284 (Pubitemid 28283892)
38. Dumler F, Kilates C. Metabolic and nutritional complications of renal transplantation. J Ren Nutr 2007;17:97-102 (Pubitemid 46014463)
39. Pannu HS, Singh D, Sandhu JS. Lipid profile before and after renal transplantation - a longitudinal study. Ren Fail 2003; 25:411-417 (Pubitemid 36666461)
40. Kimak E, Solski J, Baranowicz-Gaszczyk I, et al. A long-term study of dyslipidemia and dyslipoproteinemia in stable postrenal transplant patients. Ren Fail 2006;28:483-486 (Pubitemid 44277673)
41. Jardine AG, Fellström B, Logan JO, et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. Am J Kidney Dis 2005;46:529-536 (Pubitemid 41208190)
42. Coresh J, Longenecker JC, Miller ER III, et al. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 1998;9(Suppl 12):S24-30
43. Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004;291:451-459 (Pubitemid 38129749)
44. Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008;336:645-651
45. Farwell D, Gollob MH. Risk stratification for sudden death in heart failure. Minerva Cardioangiol 2007;55:379-384 (Pubitemid 47066401)
46. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389 (Pubitemid 24365311)
47. Wanner C, Krane V, Marz W, et al.; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-248
48. Holdaas H, Fellström B, Jardine AG, et al.; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003;361:2024-2031
49. Kaisar MO, Isbel NM, Johnson DW. Recent clinical trials of pharmacologic cardiovascular interventions in patients with chronic kidney disease. Rev Recent Clin Trials 2008;3:79-88
50. Herzog CA. Don't forget the defibrillator in the dialysis unit. Nephrol Dial Transplant 2004;19:2959-2960 (Pubitemid 40057614)
51. McCullough PA. Cardiovascular care in end-stage renal disease. Adv Chronic Kidney Dis 2004;11:245
52. Levin A. Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge. Kidney Int Suppl 2002;80:35-38 (Pubitemid 34534156)
53. Zamboli P, De Nicola L, Minutolo R, et al. Heart failure in chronic kidney disease: from epidemiology to therapy. G Ital Nefrol 2007;24:574-583
54. Stewart GA, Gansevoort RT, Mark PB, et al. Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney Int 2005;67:217-226 (Pubitemid 40019243)
55. Haydar AA, Covic A, Colhoun H, et al. Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients. Kidney Int 2004;65:1790-1794 (Pubitemid 38591027)
56. Seliger SL, Weiss NS, Gillen DL, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002;61:297-304 (Pubitemid 34075157)
57. Asselbergs FW, Diercks GF, Hillege HL, et al.; Prevention of renal and vascular endstage disease intervention trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004;110:2809-2816
58. Steinmetz OM, Panzer U, Stahl RA, et al. Statin therapy in patients with chronic kidney disease: to use or not to use. Eur J Clin Invest 2006;36:519-527 (Pubitemid 44086766)
59. Dogra G, Irish A, Chan D, et al. A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD. Am J Kidney Dis 2007;49:776-785 (Pubitemid 46802930)
60. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106: 3143-3421
61. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22 (Pubitemid 34756487)
62. Sever PS, Dahlöf B, Poulter NR, et al.; ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than- average cholesterol concentrations, in the Anglo- Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-1158
63. Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004;110:1557-1563 (Pubitemid 39297976)
64. Sandhu S, Wiebe N, Fried LF, et al. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006;17: 2006-2016 (Pubitemid 44036185)
65. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001;59:260-269 (Pubitemid 32055234)
66. Vidt DG, Harris S, McTaggart F, et al. Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. Am J Cardiol 2006;97:1602-1606 (Pubitemid 43737029)
67. Bianchi S, Bigazzi R, Caiazza A, et al. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 2003;41:565-570 (Pubitemid 36278373)
68. van Dijk MA, Kamper AM, van Veen S, et al. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2001;16:2152-2157 (Pubitemid 33062136)
69. Tonolo G, Melis MG, Formato M, et al. Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000;30:980-987
70. Lee TM, Su SF, Tsai CH. Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension 2002;40:67-73 (Pubitemid 34755981)
71. Tonelli M, Moyé L, Sacks FM, et al.; Cholesterol and Recurrent Events Trial Investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003; 14:1605-1613
72. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004;57:728-734 (Pubitemid 38901488)
73. Kano K, Nishikura K, Yamada Y, et al. Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria. Clin Nephrol 2003;60:85-89 (Pubitemid 36975182)
74. Kano K, Nishikura K, Yamada Y, et al. No effect of fluvastatin on the bone mineral density of children with minimal change glomerulonephritis and some focal mesangial cell proliferation, other than an ameliorating effect on their proteinuria. Clin Nephrol 2005;63:74-79 (Pubitemid 40298040)
75. Shepherd J, Kastelein JJ, Bittner V, et al.; Treating to New Targets Investigators. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2007;2:1131-1139
76. Rahman M, Baimbridge C, Davis BR, et al.; ALLHAT Collaborative Research Group. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Kidney Dis 2008; 52:412-424
77. Douglas K, O'Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 2006;145:117-124 (Pubitemid 46780585)
78. Tonelli M, Isles C, Craven T, et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 2005;112:171-178 (Pubitemid 40982298)
79. Kshirsagar AV, Shoham DA, Bang H, et al. The effect of cholesterol reduction with cholestyramine on renal function. Am J Kidney Dis 2005;46:812-819 (Pubitemid 41505454)
80. Kostapanos MS, Milionis HJ, Gazi I, et al. Rosuvastatin increases alpha-1 microglobulin urinary excretion in patients with primary dyslipidemia. J Clin Pharmacol 2006;46:1337-1343 (Pubitemid 44564363)
81. Zipes DP, Zvaifler NJ, Glassock RJ, et al. Rosuvastatin: an independent analysis of risks and benefits. Med Gen Med 2006;8:73 (Pubitemid 43905380)
82. Kasiske BL, Wanner C, O'Neill WC. An assessment of statin safety by nephrologists. Am J Cardiol 2006;97 (Suppl 8A):82C-85C
83. Akdim F, van Leuven SI, Kastelein JJ, et al. ES. Pleiotropic effects of statins: stabilization of the vulnerable atherosclerotic plaque? Curr Pharm Des 2007;13:1003-1012
84. John S, Schlaich M, Langenfeld M, et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients. Circulation 1998;98:211-216
85. Ott C, Schlaich MP, Schmidt BM, et al. Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. Atherosclerosis 2008;196:704-711
86. Asher J, Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich) 2007;9:622-628
87. Ridker PM, Rifai N, Clearfield M, et al.; Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-1965
88. Kinlay S. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol 2007;49:2003-2009 (Pubitemid 46734641)
89. Shepherd J, Kastelein JJ, Bittner V, et al.; TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008;51:1448-1454
90. Shepherd J, Kastelein JP, Bittner VA, et al.; Treating to New Targets Steering Committee and Investigators. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc 2008;83:870-879
91. Tonelli M, Moyé L, Sacks FM, et al.; Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003;138:98-104
92. Collins R, Armitage J, Parish S, et al.; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol- lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-2016
93. Lins RL, Matthys KE, Billiouw JM, et al. Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study. Clin Nephrol 2004;62:287-294 (Pubitemid 39386805)
94. Navaneethan SD, Shrivastava R. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev 2004;4:CD004289
95. Mason NA, Bailie GR, Satayathum S, et al. HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 2005;45:119-126 (Pubitemid 40038052)
96. Holdaas H, Fellström B, Jardine AG, et al.; ALERT Study Group. Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation. Nephrol Dial Transplant 2005;20:974-980
97. Holdaas H, Fellström B, Cole E, et al.; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 2005;5:2929-2936
98. Holdaas H, Wanner C, Abletshauser C, et al. The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials. Int J Cardiol 2007;117:64-74 (Pubitemid 46402940)
99. Chonchol M, Cook T, Kjekshus J, et al. Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. Am J Kidney Dis 2007;49:373-382 (Pubitemid 46320760)
100. Svensson M, Schmidt EB, Jørgensen KA, et al.; OPACH Study Group. N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: a randomized, placebo-controlled intervention trial. Clin J Am Soc Nephrol 2006;1:780-786
101. Agarwal R. Effects of statins on renal function. Mayo Clin Proc 2007;82:1381-1394 (Pubitemid 350060135)
102. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 2003;84:S207-10 (Pubitemid 36513411)
103. Fellström B, Zannad F, Schmieder R, et al.; AURORA Study Group. Effect of rosuvastatin on outcomes in chronic haemodialysis patients - design and rationale of the AURORA study. Curr Control Trials Cardiovasc Med 2005;6:9
104. Fellström B, Holdaas H, Jardine AG, et al.; AURORA Study Group. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. Kidney Blood Press Res 2007;30:314-322
105. Rossebø AB, Pedersen TR, Boman K, et al.; SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343-1356 Epub ahead of print
106. Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008;359:1357-1366
107. Fassett RG, Ball MJ, Robertson IK, et al. The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease. BMC Nephrol 2008;9:4